Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 40, Issue 12, 1997, Pages 1820-1826

  Rewcastle, Gordon W ^a   Bridges, Alexander J ^b   Fry, David W ^b   Rubin, J Ronald ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3 BROMOPHENYL)AMINO] 6 (METHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME ISOLATION; NONHUMAN; RECEPTOR SOLUBILIZATION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030968950     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960879m     Document Type: Article

References (27)

1. Veale, D.; Kerr, N.; Gibson, G. J.; Kelly, P. J.; Harris, A. L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br. J. Cancer 1993, 68, 162-165.
2. Fontanini, G.; Vignati, S.; Bigini, D.; Mussi, A.; Lucchi, H.; Angeletti, C. A.; Pingitore, R.; Pepe, S.; Basolo, F.; Bevilacqua, G. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur. J. Cancer 1995, 31A, 178-183.
3. Earp, H. S.; Dawson, T. L.; Li, X.; Yu, H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 1995, 35, 115-132.
4. Wright, C.; Nicholson, S.; Angus, B.; Sainsbury, J. R. C.; Farndon, J.; Cairns, J.; Harris, A. L.; Horne, C. H. W. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 1992, 65, 118-121.
5. Modjtahedi, H.; Hickish, T.; Nicolson, M.; Moore, J.; Styles, J.; Eccles, S.; Jackson, E.; Salter, J.; Sloane, J.; Spencer, L.; Priest, K.; Smith, I.; Dean, C.; Gore, M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996, 73, 228-235.
6. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
7. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
8. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitorof the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
9. Denny, W. A.; Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Kraker, A. J. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP site of the epidermal growth factor receptor in vitro. Clin. Exp. Pharm. Physiol. 1996, 23, 424-427.
10. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
11. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
12. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
13. Gazit, A.; Chen, J.; App, H.; McMahon, G.; Hirth, P.; Chen, I.; Levitzki, A. Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg. Med. Chem. 1996, 4, 1203-1207.
14. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
15. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
16. Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadsky, J. M. 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystrallogr. 1993, D49, 362-365.
17. Himmelsbach, F.; Von Rueden, T.; Dahmann, G.; Metz, T. Preparation of 4-(phenylamino)pyrimido[5,4-d]pyrimidines as epidermal growth factor antagonists. PCT Intl. Application WO 9607657, March 1996; Chem. Abstr. 1996, 125, 33669c.
18. Himmelsbach, F.; Von Rueden, T.; Dahmann, G.; Metz, T. Preparation of 4-(phenylamino)pyrimido[5,4-d]pyrimidines as epidermal growth factor antagonists. PCT Intl. Application WO 9607657, March 1996; Chem. Abstr. 1996, 125, 33669c.
19. Gallemaers, J.-P.; Christophe, D.; Promel, R. Synthesis and conversion of 5-amino-4-pyrimidinecarboxylic acids into 4-hydroxypyrimidines via their diazonium salts. Tetrahedron Lett. 1976, 693-694.
20. Albert, A. Annelation of a pyrimidine ring to an existing ring. Adv. Heterocycl. Chem. 1982, 32, 1-81.
21. Montgomery, J. A.; Temple, C., Jr. Synthesis of potential anticancer agents. XII. 9-Alkyl-6-substituted purines. J. Am. Chem. Soc. 1958, 80, 409-411.
22. Montgomery, J. A.; Fitzgibbon, W. E., Jr. Diethoxymethyl acetate. A cyclization agent useful in the preparation of purines and other nitrogen heterocycles. Nucleic Acid Chem. 1978, 2, 995-997.
23. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidinea; a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
24. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
25. Woodburn, J. R.; Barker, A. J.; Wakeling, A. E.; Valcaccia, B. E.; Cartlidge, S. A.; Davies, D. H. 6-Amino-4-(3-methylphenylamino)quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts. Proc. Am. Assoc. Cancer Res. 1996, 37, 390 (Abstract 2665).
26. Denny, W. A.; Atwell, G. J.; Baguley, B. C. Potential Antitumor Agents. Part 39. Anilino ring geometry of amsacrine and derivatives: relationship to antitumor activity. J. Med. Chem. 1983, 26, 1625-1630.
27. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.